PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar nveagle (37.17) Submitted: 1/18/2012 12:22:04 PM : Outperform Start Price: $6.14 PDLI Score: +4.21

Potential in the long term.

Featured Broker Partners


Advertisement